Establishment Labs Holdings Inc. $ESTA Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 59.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 115,876 shares of the company’s stock after buying an additional 43,164 shares during the period. Assenagon Asset Management S.A. owned 0.40% of Establishment Labs worth $8,445,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Establishment Labs in the third quarter valued at about $34,000. State of Wyoming purchased a new position in shares of Establishment Labs during the third quarter worth about $71,000. Osaic Holdings Inc. grew its holdings in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. PharVision Advisers LLC acquired a new position in Establishment Labs in the 3rd quarter valued at about $203,000. Finally, Brian Low Financial Group LLC acquired a new position in Establishment Labs in the 3rd quarter valued at about $223,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 33,925 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75. Following the sale, the director owned 1,223,579 shares in the company, valued at $73,891,935.81. This trade represents a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.09% of the stock is currently owned by corporate insiders.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $55.31 on Friday. The business’s fifty day moving average price is $68.98 and its two-hundred day moving average price is $61.88. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $83.31. The stock has a market cap of $1.62 billion, a PE ratio of -31.79 and a beta of 0.91. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the company earned ($1.19) EPS. On average, analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ESTA. JPMorgan Chase & Co. boosted their target price on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Stephens raised their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday. Canaccord Genuity Group boosted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.86.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.